• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Insight Molecular Diagnostics Inc (IMDX)

Common Shares
Sell: $5.70|Buy: $7.20|Change: 0.17 (-2.48%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx.

Address

1010 Atlantic Avenue
Suite 102
Alameda
CA
USA
94501

Telephone

+1 510 7750515

Website

https://www.imdxinc.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Insight Molecular Diagnostics Inc Third Quarter Earnings Conference Call for 20262026-11-10T17:00:00
Insight Molecular Diagnostics Inc Third Quarter Earnings Results for 20262026-11-10T00:00:00
Insight Molecular Diagnostics Inc Second Quarter Earnings Conference Call for 20262026-08-11T17:00:00
Insight Molecular Diagnostics Inc Second Quarter Earnings Results for 20262026-08-11T00:00:00
Insight Molecular Diagnostics Inc Annual General Meeting for 20262026-06-26T10:00:00
OncoCyte Corp First Quarter Earnings Conference Call for 20262026-05-12T14:00:00
OncoCyte Corp First Quarter Earnings Results for 20262026-05-12T00:00:00
OncoCyte Corp Fourth Quarter Earnings Conference Call for 20252026-03-24T14:00:00
OncoCyte Corp Fourth Quarter Earnings Results for 20252026-03-24T00:00:00
OncoCyte Corp Annual Report for 20252026-03-24T00:00:00

Previous key dates

NameKey Date
Insight Molecular Diagnostics Inc Third Quarter Earnings Conference Call for 20252025-11-10T17:00:00
Insight Molecular Diagnostics Inc Third Quarter Earnings Results for 20252025-11-10T00:00:00
Lake Street Capital Markets 9th Annual Best Ideas Growth Conference (BIG9)2025-09-11T00:00:00
H.C. Wainwright 27th Annual Global Investment Conference2025-09-08T17:00:00
Insight Molecular Diagnostics Inc Second Quarter Earnings Conference Call for 20252025-08-11T17:00:00
Insight Molecular Diagnostics Inc Second Quarter Earnings Results for 20252025-08-11T00:00:00
Insight Molecular Diagnostics Inc Annual General Meeting for 20252025-06-27T10:00:00
OncoCyte Corp First Quarter Earnings Conference Call for 20252025-05-12T14:00:00
OncoCyte Corp First Quarter Earnings Results for 20252025-05-12T00:00:00
24th Annual Needham Virtual Healthcare Conference2025-04-07T15:45:00
OncoCyte Corp Fourth Quarter Earnings Conference Call for 20242025-03-24T14:00:00
OncoCyte Corp Fourth Quarter Earnings Results for 20242025-03-24T00:00:00
OncoCyte Corp Annual Report for 20242025-03-24T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.